Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.
Last trade$7.27
Day change+$0.03 (+0.41%)
Day range$7.07 – $7.86
Volume17,181
Market cap$18M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$17.8M
Price / earnings
—
Price / book
10.37×
Price / sales
2.83×
EV / sales
2.92×
EV / EBITDA
-1.19×
Profitability
Earnings per share
-$11.39
Return on assets
-305.37%
Return on equity
-1,631.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.38×
Current ratio
1.02×
Quick ratio
0.22×
Cash ratio
0.01×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PMI, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$2.95M
$1.15M
$1.01M
$1.19M
Cost of revenue
$2.34M
$875K
$598K
$1.32M
Gross profit
$616K
$275K
$411K
-$130K
Selling, general and administrative
$3.87M
$2.89M
$2.87M
$2.41M
Research and development
$1.37M
$1.9M
$547K
$951K
Total operating expenses
$5.25M
$4.79M
$3.41M
$3.36M
Operating income
-$4.63M
-$4.51M
-$3M
-$3.49M
Interest expense
-$89K
$0
-$2.29M
$0
Income before taxes
-$5.65M
-$7.62M
-$4.29M
-$10.43M
Income taxes
$7K
$0
$4K
$0
Net income
-$5.66M
-$7.62M
-$4.29M
-$10.43M
Net income attributable to common shareholders
-$5.66M
-$7.62M
-$4.29M
-$10.43M
EBITDA
-$4.58M
-$4.47M
-$2.96M
-$3.45M
Basic earnings per share
-$3.05
-$5.00
-$2.91
-$9.50
Diluted earnings per share
-$3.05
-$5.00
-$2.91
-$9.50
Recent news
Company coverage with links to the original publishers.
Picard Medical reported Q3 2026 results showing positive gross profit for the third consecutive quarter, with net loss narrowing 79% to $2.2 million. Nine-month revenue increased 10% to $4.3 million with gross profit improving to $1.0 million from a prior-year loss. The company completed repayment of its Senior Secured Note and expects Q4 2026 product sales to exceed prior year, though it faces capital needs and substantial doubt about continuing as a going concern.
Picard Medical announced a 1-for-50 reverse stock split effective July 31, 2026, to maintain NYSE American listing compliance. The split was approved by stockholders on July 17, 2026. The company, parent of SynCardia Systems (maker of the FDA and Health Canada-approved total artificial heart), aims to position itself for growth while advancing its next-generation Emperor platform.
Kuehn Law is investigating whether officers and directors of Picard Medical Inc. breached fiduciary duties by failing to disclose a fraudulent stock promotion scheme involving social media misinformation, coordinated share dumping by insiders through offshore accounts, and omission of risk disclosures related to artificial trading activity that inflated stock prices.
Picard Medical announced successful completion of preclinical implant studies for its next-generation Emperor Total Artificial Heart (TAH) at University of Arizona and Banner University Medical Center. The Emperor TAH demonstrated stable hemodynamic support with an independent dual motor ventricular system designed to advance toward a fully implantable artificial heart system. Three acute implant procedures were completed with no device-related failures observed.
Picard Medical, parent company of SynCardia Systems, announced its participation in the ISHLT 2026 Annual Meeting in Toronto. The company will present a poster on the Emperor Total Artificial Heart, a next-generation fully implantable solution for end-stage heart failure, and exhibit at booth 409 to showcase its SynCardia Total Artificial Heart technology.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 29, 2008
$0.125
Jan 15, 2009
unknown
Sep 26, 2008
$0.125
Oct 15, 2008
unknown
Jun 26, 2008
$0.625
Jul 15, 2008
unknown
Mar 27, 2008
$0.625
Apr 15, 2008
unknown
Dec 27, 2007
$2.625
Jan 15, 2008
unknown
Stock splits
Historical share-structure events and their execution dates.